Logo

Ambit, Bristol Myers-Squibb Expand Kinase Screening Pact

Oct 31, 2007
NEW YORK (GenomeWeb News) - Ambit Biosciences has expanded an agreement with Bristol-Myers Squibb for kinase discovery research, Ambit said today.
 
Under the agreement, Ambit will use its KinomeScan method to screen small-molecule libraries against "a large number of human kinases," Ambit said, continuing a relationship begun in 2004.
 
Ambit's KinomeScan uses binding assays to determine how compounds bind to intended and unintended kinases, the company said.
 
The agreement calls for Bristol Myers-Squibb to give Ambit an undisclosed cash payment on the front end, and Ambit will retain the rights to certain of Bristol Myers-Squibb's preclinical and clinical compounds.

Breaking News
The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.